Altamira Therapeutics Ltd.
CYTO · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.48 | -0.00 |
| FCF Yield | 0.00% | 0.00% | -160.14% | -78.81% |
| EV / EBITDA | 0.00 | 0.00 | -14.14 | -19.89 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | -74.47% | -77.43% |
| Gross Margin | 0.00% | 0.00% | -101.18% | -101.18% |
| Cash Conversion Ratio | 1.42 | 1.42 | 0.18 | 0.16 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | 44.28% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | -148.93% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | -8.29 | -8.01 |
| Interest Coverage | 0.00 | 0.00 | -3.92 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.39 | 0.39 |
| Cash Conversion Cycle | 0.00 | 0.00 | -91.84 | 283.77 |